ENTA — Enanta Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $119.04m
- -$96.31m
- $67.64m
- 41
- 39
- 51
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.06 | ||
| Price to Tang. Book | 1.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.83% | ||
| Return on Equity | -69.1% | ||
| Operating Margin | -165.71% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 122.47 | 97.07 | 86.16 | 79.2 | 67.64 | 62.79 | 55.11 | -19.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Directors
- Bruce Carter NEC (78)
- Jay Luly PRE (65)
- Paul Mellett CFO (66)
- Yat Sun Or SVP (69)
- Nathaniel Gardiner SVP (68)
- Nathalie Adda SVP (56)
- Tara Kieffer SVP (44)
- Brendan Luu SVP (47)
- Mark Foletta IND (61)
- Yujiro Hata IND (47)
- Kristine Peterson IND (62)
- Lesley Russell IND (61)
- Terry Vance IND (65)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 25th, 1995
- Public Since
- March 21st, 2013
- No. of Shareholders
- 17
- No. of Employees
- 131
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 21,332,544
- Address
- 4 Kingsbury Avenue, WATERTOWN, 02472
- Web
- https://www.enanta.com/
- Phone
- +1 6176070800
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ENTA
Q3 2025 Enanta Pharmaceuticals Inc Earnings Release
Similar to ENTA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Enanta Pharmaceuticals share price?
As of Today at 20:26 UTC, shares in Enanta Pharmaceuticals are trading at $5.58. This share price information is delayed by 15 minutes.
How has the Enanta Pharmaceuticals share price performed this year?
Shares in Enanta Pharmaceuticals last closed at $5.58 and the price had moved by -55.29% over the past 365 days. In terms of relative price strength the Enanta Pharmaceuticals share price has underperformed the S&P500 Index by -58.73% over the past year.
What are the analyst and broker recommendations for Enanta Pharmaceuticals?
The overall consensus recommendation for Enanta Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Enanta Pharmaceuticals dividend yield?
Enanta Pharmaceuticals does not currently pay a dividend.
Does Enanta Pharmaceuticals pay a dividend?
Enanta Pharmaceuticals does not currently pay a dividend.
When does Enanta Pharmaceuticals next pay dividends?
Enanta Pharmaceuticals does not currently pay a dividend.
How do I buy Enanta Pharmaceuticals shares?
To buy shares in Enanta Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enanta Pharmaceuticals?
As of the previous close price of $5.58, shares in Enanta Pharmaceuticals had a market capitalisation of $119.04m.
Where are Enanta Pharmaceuticals shares listed?
Here are the trading details for Enanta Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ENTA
What kind of share is Enanta Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Enanta Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enanta Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Enanta Pharmaceuticals is $16.83. That is 201.61% above the last closing price of $5.58.
Analysts covering Enanta Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.52 for the next financial year.
Find out moreWhat is the trend in the Enanta Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enanta Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -49.65%.
As of the last closing price of $5.58, shares in Enanta Pharmaceuticals were trading -39.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enanta Pharmaceuticals PE Ratio?
The Enanta Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enanta Pharmaceuticals?
Enanta Pharmaceuticals' management team is headed by:
- Bruce Carter - NEC
- Jay Luly - PRE
- Paul Mellett - CFO
- Yat Sun Or - SVP
- Nathaniel Gardiner - SVP
- Nathalie Adda - SVP
- Tara Kieffer - SVP
- Brendan Luu - SVP
- Mark Foletta - IND
- Yujiro Hata - IND
- Kristine Peterson - IND
- Lesley Russell - IND
- Terry Vance - IND